Welcome to the Oncomine Blog
Healthcare Economic Analysis Makes Case for In-house NGS
08/07/2023 |
Education
Next-generation sequencing (NGS) has become an increasingly important tool for identifying molecular biomarkers that can help guide treatment...
-
NGS Enables Precision Oncology in Community-Based Hospitals
Next-generation sequencing (NGS) technology has changed cancer treatment by enabling pathologists an... -
How Diagnostics can Revolutionize Patient Care: Insights from the Precision Medicine Leader Summit
Precision medicine is a holistic approach to healthcare that combines knowledge of an individuals’ g... -
University of Munich Evaluates the Oncomine Comprehensive Plus Assay for HRD Detection
Our OncomineWorld event in 2021 brought thousands of professionals together from around the world to... -
Case Study: High-Quality, Cost-Effective Genomic Testing and Genetic Profiling using NGS
In a recent case study interview, pathologist Federico Jauk, head of the Sequencing Laboratory at th... -
Q&A: An Inside Look at Immune Repertoire Assay Development with Dr. Geoffrey Lowman
Dr. Geoffrey Lowman Senior Staff Scientist, Molecular Biology, Clinical Sequencing Division Thermo F... -
UAB Study Evaluates the Oncomine Myeloid Research Assay GX on the Genexus System
Performance of the Oncomine Myeloid Research Assay GX Craig Mackinnon, MD, PhD, Director of Genomic ... -
Let’s Do It Ourselves - A global expert consensus is emerging: by retaining oncology biomarker testing in-house, healthcare management and patient care benefit significantly
Over the last decade, precision oncology therapies dependent on biomarker-based diagnostics have pro... -
A Comprehensive Answer for Cancer: Is Comprehensive Genomic Profiling Always the Right Approach?
What is comprehensive genomic profiling (CGP)? CGP is the simultaneous detection of all classes of g... -
Biomarker Tests for Precision Oncology: DIY or Pay-for-Service?
Cancer patient management of is increasingly driven by biomarker assays – but how should we manage t...